Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions

A method for preparing a pharmaceutical composition comprising:

• taking polyoxyethylated castor oil which if diluted 1:10 in water has a pH greater than 6 and aging the polyoxyethylated castor oil by exposing the polyoxyethylated castor oil to a gas comprising oxygen for a period of time, the exposure to the gas over the period of time causing an acidity of the polyoxyethylated castor oil to increase;
• and
• forming a pharmaceutical composition comprising the aged polyoxyethylated castor oil, ethanol and paclitaxel;
• wherein at least 80% of the paclitaxel potency is retained by the pharmaceutical composition after the pharmaceutical composition is stored for at least 7 days at 40° C.

A method for preparing a pharmaceutical composition of paclitaxel comprising:

• taking polyoxyethylated castor oil which if diluted 1:10 in water has a pH greater than 5 and aging the polyoxyethylated castor oil by exposing the polyoxyethylated castor oil to a gas comprising oxygen until the aged polyoxyethylated castor oil, if diluted 1:10 in water, has a pH equal to or less than 4.9;
• and
• forming a pharmaceutical composition comprising the aged polyoxyethylated castor oil, ethanol and paclitaxel;
• wherein at least 80% of the paclitaxel potency is retained by the pharmaceutical composition after the pharmaceutical composition is stored for at least 7 days at 40° C.

A pharmaceutical composition comprising:

• polyoxyethylated castor oil that has been modified by taking polyoxyethylated castor oil which if diluted 1:10 in water has a pH greater than 6 and aging the polyoxyethylated castor oil by exposing the polyoxyethylated castor oil to a gas comprising oxygen until the aged polyoxyethylated castor oil, if diluted 1:10 in water, has a pH equal to or less than 5.9;
• and
• paclitaxel;
• wherein the pharmaceutical composition does not comprise an agent added to the polyoxyethylated castor oil that functions to increase the acidity of the polyoxyethylated castor oil.

A pharmaceutical composition comprising:

• polyoxyethylated castor oil that has been modified by taking polyoxyethylated castor oil which if diluted 1:10 in water has a pH greater than 5 and aging the polyoxyethylated castor oil by exposing the polyoxyethylated castor oil to a gas comprising oxygen until the aged polyoxyethylated castor oil, if diluted 1:10 in water, has a pH equal to or less than 4.9;
• and
• paclitaxel;
• wherein at least 80% of the paclitaxel potency is retained by the pharmaceutical composition after the pharmaceutical composition is stored for at least 7 days at 40° C.

A pharmaceutical comprising:

• a sealed vial comprising
• polyoxyethylated castor oil that has been modified by taking polyoxyethylated castor oil which if diluted 1:10 in water has a pH greater than 6 and aging the polyoxyethylated castor oil by exposing the polyoxyethylated castor oil to a gas comprising oxygen until the aged polyoxyethylated castor oil, if diluted 1:10 in water, has a pH equal to or less than 5.9;
• and
• paclitaxel;
• wherein the pharmaceutical does not comprise an agent added to the polyoxyethylated castor oil that functions to increase the acidity of the polyoxyethylated castor oil.

A pharmaceutical comprising:

• a sealed vial comprising
• polyoxyethylated castor oil that has been modified by taking polyoxyethylated castor oil which if diluted 1:10 in water has a pH greater than 6 and aging the polyoxyethylated castor oil by exposing the polyoxyethylated castor oil to a gas comprising oxygen until the aged polyoxyethylated castor oil, if diluted 1:10 in water, has a pH equal to or less than 5.9;
• and
• paclitaxel;
• wherein at least 80% of the paclitaxel potency is retained by the pharmaceutical after the pharmaceutical is stored for at least 7 days at 40° C.

A pharmaceutical comprising:

• a sealed vial comprising
• polyoxyethylated castor oil that has been modified by taking polyoxyethylated castor oil which if diluted 1:10 in water has a pH greater than 5 and aging the polyoxyethylated castor oil by exposing the polyoxyethylated castor oil to a gas comprising oxygen until the aged polyoxyethylated castor oil, if diluted 1:10 in water, has a pH equal to or less than 4.9;
• and
• paclitaxel;
• wherein at least 80% of the paclitaxel potency is retained by the pharmaceutical after the pharmaceutical is stored for at least 7 days at 40° C.